Abstract Pharmacokinetic/pharmacodynamic (PK/PD) modelling is the initial step in the semi‐
mechanistic approach for optimizing dosage regimens for systemically acting antimicrobial …

Complicated intra-abdominal infections (cIAIs) are commonly associated with
multimicroorganisms and treatment choices are becoming narrower due to developing …

The discovery of antibiotics has long been regarded as one of the most significant medical
achievements of the twentieth century. Antibiotics have saved millions of lives (1) and …

By, in effect, rendering pharmacokinetics an experimentally adjustable parameter, the ability
to perform feedback-controlled dosing informed by high-frequency in vivo drug …

Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that
exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic …

The emergence of multidrug-resistant (MDR) Gram-negative bacteria has become a global
problem. Among MDR Gram-negative bacteria, carbapenem-resistant Enterobacteriaceae …

Objectives To determine the in vitro activities of novel and comparator antibiotics against
Gram-negative bacteria (GNB) in Taiwan. Methods Isolates of Escherichia coli (n= 335) …

Eravacycline is a novel fluorocycline antibiotic with potent activity against a broad range of
pathogens, including strains with tetracycline and other drug resistance phenotypes. The …

Tigecycline, a tetracycline derivative, shows atypical plasma protein binding behavior. The
unbound fraction decreases with increasing concentration at therapeutic concentrations …

The unbound fraction of a drug in plasma can profoundly influence both its
pharmacokinetics and pharmacodynamics. For most drugs, the unbound fraction is relatively …